Advisory: Alert on clinical study wrongly tagged to Cantex Mine Development withdrawn
20/04/2023 13:51
April 20 (Reuters) - An alert on Cantex Pharmaceuticals and Michigan
Medicine initiating a study to determine the safety and efficacy of the drug
Azeliragon in the treatment of patients hospitalized for COVID-19 has been
withdrawn as it was inadvertently tagged to Cantex Mine Development Corp CD.V ,
an unrelated company.
For the correct alert from Cantex Pharmaceuticals, click urn:newsml:reuters.com:*:nFWN36N2H2
STORY_NUMBER: FWN36N02R
STORY_DATE: 20/04/2023
STORY_TIME: 12:00:35 PM GMT
((Bangalore.newsroom@thomsonreuters.com))